Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neuroendocrine Tumors 4Colorectal Neoplasms 4Rectal Neoplasms 3Diarrhea 3Carcinoid Tumor 3Gastro-enteropancreatic neuroendocrine tumor 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Malignant Carcinoid Syndrome 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma 1Breast Neoplasms 1Anus Neoplasms 1Adenoma, Islet Cell 1

Interventions

Fluorouracil 72Leucovorin 71Oxaliplatin 47Irinotecan 31Capecitabine 24Bevacizumab 23Folfox protocol 20Cetuximab 15Chemotherapy, Adjuvant 13Celecoxib 7Aspirin 6Laparoscopy 5XELOX 4Panitumumab 4Neoadjuvant Therapy 4Levamisole 4dehydroftorafur 3Tegafur 3Surgical Procedures, Operative 3Observation 3Floxuridine 3vatalanib 2tislelizumab 2pertuzumab 2encorafenib 2atezolizumab 2Trastuzumab 2Standard of Care 2Semaxinib 2Selenium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Colonic Neoplasms × Octreotide × Clear all
NCT00003057 2023-06-18

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
500 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT00006269 2012-05-25

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Novartis

Phase 3 Terminated
89 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡